Conference Coverage

Delaying Adalimumab Tx Impairs Long-Term Response

Publish date: July 6, 2012

 

AT THE ANNUAL EUROPEAN CONGRESS OF RHEUMATOLOGY

Dr. Keystone disclosed financial relationships with Abbott, Amgen, AstraZeneca, Biotest, Bristol-Myers Squibb, Centocor, Genentech, Genzyme, Merck, Novartis, Nycomed, Pfizer, Roche, and UCB.

Pages

Recommended Reading

Interleukin-17 Inhibitor Scores in Rheumatoid Arthritis Trial
MDedge Internal Medicine
Is Tocilizumab Monotherapy for RA Losing Luster?
MDedge Internal Medicine
Small Study: Reduced Anti-TNF Dose Still Effective
MDedge Internal Medicine
New JAK Inhibitors Show RA Safety, Efficacy
MDedge Internal Medicine
Synovitis in RA Identifies High Progression Risk
MDedge Internal Medicine
High Interferon Response, Low B Cells Presage Rheumatoid Arthritis
MDedge Internal Medicine
Tocilizumab Beats Adalimumab in Monotherapy RA Trial
MDedge Internal Medicine
VTE Risk Pumped Up in Rheumatoid Arthritis
MDedge Internal Medicine
FDA Panel Considers Metal-on-Metal Hip Replacements
MDedge Internal Medicine
New Biomarkers Identify Tocilizumab Responders Super Early
MDedge Internal Medicine